NEW YORK: Pfizer reported a jump in second-quarter profits on Thursday behind a near doubling of revenues driven by sales of its COVID-19 vaccine and therapeutic drug Paxlovid.
US officials last month approved emergency authorisation to Pfizer and Moderna for COVID-19 vaccines in under-five-year-olds, the final age group awaiting immunisation in most countries.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: